Table 4 Comparison of safety monitoring tests done in the present study with previously reported studies in different settings
Therapy | Test | Sri Lanka present study (2014–15) | UK (2008–10), (Paton et al., 2013) | USA 2004–06 (Kilbourne et al., 2007) | Brazil 2009 (Souza et al., 2013) | |
|---|---|---|---|---|---|---|
2008 | 2010 | |||||
Lithium | Serum lithium | 58.5% (past year) 45.7% (past 6 months) | 90% (1–4 tests in an year) | 96% (1–4 tests in 1 year) | 19% (past 6 months) | 19% (past year) |
TFT | 18.3% (Past year) | 82% (1–2 tests per year) | 92% (1–2 tests per year) | 39% (past 6 months) | Not studied | |
UC and E | 23.8%: Urea and Creatinine 20.7%: Electrolytes (Past year) | 81% (1–2 or more testsper year) | 90% (1–2 or more tests per year) | 83% (past 6 months) | Not studied | |
Sodium valproate | TDM | No records | Not studied | Not studied | 56% (past 6 months) | Not studied |
FBC | 7.6% (past year) | Not studied | Not studied | 72% (past 6 months) | Not studied | |
LFT | 16% (past year) | Not studied | Not studied | 76% (past 6 months) | Not studied | |
Carbamazepine | TDM | No records | Not studied | Not studied | 42.9% (past 6 months) | Not studied |
FBC | 1 record in the past year | Not studied | Not studied | 72% (past 6 months) | Not studied | |
Atypical antipsychotics | FBG | 20.5% (past year) | Not studied | Not studied | 69% (past 6 months) | Not studied |
Lipid profile | 8.6% (past year) | Not studied | Not studied | 50% (past 6 months) | Not studied | |